Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04940052 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
A Phase 3 study of Differentiated Thyroid Cancer (DTC), sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT04940052 is a Phase 3 study of Differentiated Thyroid Cancer (DTC) that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 153 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT04940052, a Phase 3 study of Differentiated Thyroid Cancer (DTC), is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG Dabrafenib
- DRUG Trametinib Placebo
- DRUG Dabrafenib placebo
Study Locations (20)
Jiangsu
- Novartis Investigative Site - Nanjing
- Novartis Investigative Site - Nanjing
- Novartis Investigative Site - Xuzhou
Other
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Beijing
Illinois
- Northwestern University Med School - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Buenos Aires
- Novartis Investigative Site - CABA
Rio de Janeiro
- Novartis Investigative Site - Rio de Janiero
Santa Catarina
- Novartis Investigative Site - Blumenau
São Paulo
- Novartis Investigative Site - São Paulo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2027-06-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04940052
The ClinicalTrials.gov registry entry for NCT04940052 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Differentiated Thyroid Cancer (DTC) appearing as the primary indexed condition, and to 4 interventions - of which Trametinib is the first listed.
NCT04940052 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Jiangsu, Other, Illinois.
Frequently Asked Questions
What is clinical trial NCT04940052 about?
NCT04940052 is a clinical study titled "Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer". The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and...
What is the current status of trial NCT04940052?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2021-11-15. Estimated completion is 2027-06-04.
What conditions does trial NCT04940052 study?
This clinical trial studies the following conditions: Differentiated Thyroid Cancer (DTC).
What interventions are being tested in trial NCT04940052?
The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG), Trametinib Placebo (DRUG), Dabrafenib placebo (DRUG).
Who is sponsoring clinical trial NCT04940052?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04940052 being conducted?
This trial has 20 study locations across Illinois, Massachusetts, Buenos Aires, Rio de Janeiro, Santa Catarina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.